These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16908974)

  • 1. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 6. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 7. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in progressive brain disorders.
    Djaldetti R; Lev N; Melamed E
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.
    Heemskerk J; Tobin AJ; Ravina B
    Nat Neurosci; 2002 Nov; 5 Suppl():1027-9. PubMed ID: 12403977
    [No Abstract]   [Full Text] [Related]  

  • 10. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 12. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins: mechanisms of neuroprotection.
    van der Most PJ; Dolga AM; Nijholt IM; Luiten PG; Eisel UL
    Prog Neurobiol; 2009 May; 88(1):64-75. PubMed ID: 19428962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.
    Porzner M; Müller T; Seufferlein T
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1765-72. PubMed ID: 19814656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacotherapy for degenerative dementias].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 2005; 160(1-2):109-17; discussion 118-22. PubMed ID: 16116815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of neurotrophic factors in experimental models of neurodegenerative disorders.
    Alberch J
    Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():63-4. PubMed ID: 9403862
    [No Abstract]   [Full Text] [Related]  

  • 19. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B; Schellenberg GD
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.